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Objective: To evaluate an informed shared decision-
making programme (ISDM-P) for people with type 2
diabetes under high fidelity conditions.
Design: Randomised, single-blinded trial with sham
control intervention and follow-up of 6 months.
Setting: Single-centre diabetes clinic providing care
according to the national disease management
programme in Germany.
Participants: 154 people with type 2 diabetes without
diagnosis of ischaemic heart disease or stroke.
Interventions: The ISDM-P is executed by diabetes
educators. Core component is a patient decision aid on
the prevention of myocardial infarction supplemented
by a 90 min group teaching session. The structurally
equivalent control intervention addresses stress issues.
Main outcome measures: Primary outcome was risk
comprehension, including realistic expectations about
benefits and harms of interventions. It was assessed by
a 12-item questionnaire after the teaching session when
patients set and prioritise their treatment goals. Key
secondary outcome was adherence to treatment goals,
operationalised as achievement of individual goals and
medication uptake. ISDM-P teaching sessions were
video-taped to monitor intervention fidelity.
Results: 72 of 77 ISDM-P and 71 of 77 control
patients completed the questionnaire (score 0–12).
ISDM-P patients achieved higher levels of risk
comprehension, mean score 8.25 vs 2.62, difference
5.63 (95% CI 4.82 to 6.44), and realistic expectations
(score 0–6), 4.51 vs 0.85, 3.67 (3.23 to 4.11). More
ISDM-P patients wished to take statins, 59.2% vs
30.4%, 28.7% (12.9% to 44.5%); more prioritised
blood pressure control, 51.4% vs 25.7%, and fewer
intensive glucose control, 33.3% vs 60%, p=0.002.
More ISDM-P patients achieved their glycated
haemoglobin goals, 95.8% vs 85.7%, 10.1% (0.6% to
19.5%). Achievement of prioritised goals and
medication uptake were comparable between groups.
Conclusions: The ISDM-P on preventive measures in
type 2 diabetes was effective under high fidelity
conditions. Involvement of diabetes educators may
facilitate implementation of the informed shared
decision-making.
Trial registration number: ISRCTN84636255.
INTRODUCTION
Cardiovascular disease is the predominant
life-threatening complication associated with
type 2 diabetes. An array of behavioural
directives is imposed on these patients such
as quitting smoking; increasing exercise;
reducing weight; and adhering to self-
monitoring, dietary and medication prescrip-
tions. Evidence on the efficacy of the recom-
mended measures is variable. Some may
even do more harm than good such as the
intensive lowering of blood glucose values by
polypharmacy.1 Patients frequently feel
demotivated and overloaded by the plethora
of medical orders. This might contribute to
poor long-term adherence even to the most
effective preventive interventions such as
blood pressure control or use of statins.2–5
Lack of patient involvement in decision-
Strengths and limitations of this study
▪ Current teaching programmes for people with
type 2 diabetes usually do not provide numerical
and comparative risk information. The informed
shared decision-making programme (ISDM-P) is
innovative in that it includes risk information and
initiates shared decision-making as recom-
mended in recent guidelines.
▪ The development of the ISDM-P was theory
based and followed the UK MRC framework for
the development and evaluation of complex
interventions.
▪ This study comprises a rigorously designed ran-
domised controlled trial and qualitative methods
to monitor intervention fidelity.
▪ Patients were blinded against the allocation, but
it was impossible to keep the diabetes educators
and other members of the healthcare teams
blinded.
▪ The study was designed as proof-of-concept,
which might limit generalisability.
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making has been suggested as an important reason for
low adherence and limited treatment success.6
Since 2012, the American Diabetes Association
(ADA) and the European Association for the Study
of Diabetes (EASD) claim a ‘patient-centred approach’
in the care of people with type 2 diabetes with
particular emphasis on shared decision-making (SDM).7
SDM is also strongly recommended in the recent
national treatment guideline for type 2 diabetes in
Germany.8
SDM is not yet implemented in diabetes care. When
we started this project, literature searches on SDM in
the context of cardiovascular prevention in type 2 dia-
betes in 20059 and updates in 200810 retrieved only
very few relevant publications. Two of them focused on
patient participation in the selection of oral antidia-
betic agents or statin treatment.11 12 A recent pragmatic
randomised controlled trial on a patient decision aid
included general practices in the Netherlands.13 The
trial failed to demonstrate an improvement of the
primary outcome measure, which was empowerment of
people with type 2 diabetes for setting and achieving
goals.
As we designed the present project, we had identified
several barriers for the implementation of SDM. They
included the lack of ready to use evidence-based patient
information (EBPI) material, time constraints on the
healthcare teams and physician encounters overloaded
with complex information.9
We have developed an informed shared decision-
making programme (ISDM-P) to address these
barriers.10 14 Main components are a decision aid and a
corresponding teaching module provided by diabetes
educators who teach and support patients to understand
risk information and to define a hierarchy of individual
treatment goals. In order to enhance practicability, the
teaching module was designed as a supplementary
session in the patient education programme that was
already integrated into the German national disease
management programme for type 2 diabetes.15
The ISDM-P is a complex intervention. It includes a
number of interdependent components that may inter-
act with contextual factors. The development process of
the ISDM-P followed the UK MRC framework for
complex interventions.16 Accordingly, development and
evaluation of the components encompassed theoretical
and empirical groundwork focusing on in-depth under-
standing of contextual interactions and implementation
processes. Details on the underlying theories, design
and pilot testing of the decision aid, the teaching cur-
riculum and the trainer modules have been published
previously.9 10 14 17 18
The objective of the present study was to assess the
efficacy of the whole programme in a randomised con-
trolled trial under high fidelity conditions. We investi-
gated if the ISDM-P leads to higher levels of risk
comprehension and realistic expectations concerning
benefits and harms of preventive options. In addition,
we evaluated if the programme helps patients to define,
to prioritise and to achieve individual treatment goals.
METHODS
The study was a parallel group, two-arm, single-blinded,
randomised controlled trial with 6 months of follow-up.
A detailed study protocol was published.14 Patients were
eligible if they were registered in the German Disease
Management Programme (DMP) for type 2 diabetes,19
were 40–69 years old, had glycated haemoglobin
(HbA1c) values between 6% and 9%, had no history of
ischaemic heart disease (International Classification of
Diseases (ICD) I20-I25) or stroke (ICD I63), and had
previously participated in structured diabetes education
sessions as typically provided within the DMP.20 Patients
were excluded if they had proliferative retinopathy,
chronic kidney disease stage 3 or higher,21 metastatic
cancer, were addicted to alcohol or cared for by a legal
guardian. The study took place at the outpatient depart-
ment of Endocrinology and Metabolic Diseases at the
Jena University Hospital, Jena, Germany. The outpatient
diabetes clinic provides standard care for a large catch-
ment area. Within the DMP, patients are followed usually
quarterly but at least once a year.
Intervention
The ISDM-P is a complex intervention.16 22 23 By defin-
ition, complex interventions comprise interdependently
acting components essential to their proper functioning.
For example, patient teaching and provider training may
act interdependently.
The underlying approach of the ISDM-P follows
Ajzen’s24 theory of planned behaviour which suggests
that behaviour is influenced by (1) individual attitudes,
(2) subjective social norms such as perceived attitudes of
family members or the healthcare team, and (3) per-
ceived and actual individual behaviour control. The
most predictive variable of SDM behaviour is intention.25
Subjective social norms and perceived behaviour control
are the most frequently identified determinants of a
health professional’s intention to perform SDM.
As one of the relevant issues, social norms of diabetes
educators and possible concerns of physicians were
addressed in the curriculum. The provision of evidence-
based information aimed at strengthening behaviour
control by resolving knowledge deficits and by realigning
unrealistic expectations.
Components of the ISDM-P are (1) an evidence-based
decision aid for patients on the prevention of heart
attack,10 (2) structured patient teaching provided by dia-
betes educators and (3) a provider training. The deci-
sion aid is supposed to be provided 2 weeks before the
teaching session. It includes EBPI on heart attack risk,
risk factors and different preventive options.10 Other
diabetes-related risks, such as stroke or microvascular
complications, are also considered. We used UKPDS
data on the combined end point for ‘any diabetes-
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related end point’ to communicate benefits and harms
of blood pressure and blood glucose control.4 26 The
decision aid is available on request from the correspond-
ing author. The patient teaching module is curriculum
based and focuses on the EBPI provided within the deci-
sion aid. A single session targets a group of 4–6 patients
and is scheduled to take 90 min. Educational elements
are illustrating wall charts and worksheets. A magnet
board is used for the visualisation of quantity risk with
100 orange and blue game pieces representing people
with and without myocardial infarction.
During the teaching session, the diabetes educator
guides through the decision-making process. This
encompasses assessing each patient’s individual heart
attack risk, providing outcome probabilities of the avail-
able preventive options, and supporting patients to set
and prioritise individual goals regarding smoking cessa-
tion, glucose control, blood pressure control and statin
treatment. At the end of the teaching session, the dia-
betes educators use specific question cards to check
patients’ understanding and to repeat information, if
necessary. We conducted four test sessions and subse-
quent focus groups with a total of 24 participants with
type 2 diabetes to pilot the teaching module.
The provider training comprises a training DVD and a
training session that includes a demonstration of the
patient teaching. The DVD is intended to prepare dia-
betes educators. It includes objectives and contents of
the teaching, basic principles of SDM and an exemplary
presentation of specific topics in the patient teaching.
The provider training focuses on the EBPI provided
within the decision aid and patient teaching. It also
addresses the implementation of the patient teaching
curriculum and the handling of the media. Piloting
showed good overall feasibility.
Comparison
In order to achieve structural equivalence, a sham
control intervention was applied. It comprised usual
care supplemented with a 90 min teaching module on
sports, nutrition and stress issues. Before the teaching
session, all participants received a brochure on stress
management.27 Diabetes educators were prepared for
the teaching session with a brief provider training.
Procedure
In December 2012, two diabetes educators were
trained in the ISDM-P by a research fellow of the
University of Hamburg (SB). Two additional diabetes
educators received the training for the control group
(provided by JK). Each of both trainings lasted about
4 hours.
The study was submitted for registration on 22
February 2013. Recruitment of patients started on 12
March 2013. Nevertheless, the registration was classified
as retrospective because the date of payment was used
as the date of finalised registration. We have notified
the registration administrator to correct the
classification from retrospective to prospective. We were
informed that this was not possible. However, the
administrator included an explanation in the registra-
tion protocol to testify that following the prospective
submission, there were no subsequent changes to the
protocol. The recruitment started after initiation of
public registration.
The electronic patient records used for DMP docu-
mentation were screened for eligible patients. Eligible
patients were marked on the records and asked for par-
ticipation during the next consultation with their phys-
ician. Baseline data were extracted from the electronic
patient records. After the patients had given informed
consent they were randomised into one of the two study
groups. Patients received either the decision aid or the
brochure on stress management.10 27 An appointment
within the next 2–4 weeks for the patient teaching was
made. When the appointment failed, a new one was
made. In order to ensure that the patients keep the
appointment date, they were contacted by phone a few
days before. At the end of the teaching session, patients
documented their individual preferences on treatment
goals regarding smoking cessation, HbA1c level, blood
pressure control (systolic blood pressure) and statin
treatment on standardised forms. Risk comprehension,
including realistic expectations on the prevention of
myocardial infarction, was assessed after the teaching
session and at 6 months follow-up. At follow-up, patients
were asked to bring their medication boxes/pill
packages to assess current medication. The overall trial
end date was supposed to be December 2013. However,
patient recruitment took longer than expected. The last
patient was enrolled in June 2014; the last teaching
session was conducted in October 2014; follow-up data
were completed in March 2015.
Outcome measures
Primary outcome was patients’ comprehension of rele-
vant risk information after the teaching session. As out-
lined in the study protocol, risk comprehension was
operationalised by the level of patient knowledge and
understanding of the notion of risk, individual heart
attack risk, and probabilities of benefits and harms of
preventive treatment options, including realistic expecta-
tions.14 We used a 12-item standardised questionnaire
with a subdomain of six items on realistic expectations.
The questionnaire was designed based on the cognitive
domain of Bloom’s taxonomy of educational objectives
aimed to evaluate different levels of comprehension.28
Each correctly answered item scored one point. We
counted missing responses as wrong answers. Item ana-
lysis resulted in good test quality (Cronbach’s α=0.87 for
the total test, and 0.86 for the subdomain of realistic
expectations).29 Comprehension, including realistic
expectations, was additionally assessed as a secondary
outcome measure at 6 months follow-up. To avoid learn-
ing effects, comprehension and realistic expectations
were not assessed at baseline.14
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Secondary outcome measures also comprised adher-
ence to individual and prioritised treatment goals.
Operationalisation of these outcomes is outlined in the
study protocol.14 We used the following variables: (1)
achievement of individual treatment goals regarding the
use of statins, levels of office systolic blood pressure and
HbA1c, and smoking; (2) achievement of the prioritised
treatment goal; (3) medication uptake as reported by
patients. The achievement of treatment goals was
assessed by comparing statin uptake, office blood pres-
sure values and HbA1c levels at follow-up with the treat-
ment goals that the patients have set and prioritised at
the end of the teaching session. Smoking status at
follow-up was assessed by using the standardised inter-
view question ‘On how many of the past 30 days did you
smoke a cigarette?’ Patients were classified as smokers if
the answer was one or more.
Sample size
We assumed patients in the ISDM group to answer 70%
of the questionnaire correctly (8 out of 12 questions),
compared with 50% in the control group (6 out of 12).
Based on an estimated 0.4 SD and striving for 80%
power with an 5% α, the study needed 64 participants in
each group (total=128) to enable detection of this 20%
absolute difference by an independent two-sided t test.
By estimating a non-responder/drop-out rate of about
15%, 154 participants needed to be recruited for
randomisation.
Randomisation and blinding
Randomisation was performed in permuted blocks of
eight patients to ensure close balance of numbers of par-
ticipants in each group and sufficient numbers of parti-
cipants (n=4) in each teaching session. Allocation of
patients was concealed and independently performed by
the Centre for Clinical Studies at the Jena University
Hospital. Potential participants were informed about the
study aim to compare two approaches of patient infor-
mation on the prevention of myocardial infarction.
Patients were kept blinded to study group allocation,
which was validated by asking patients at follow-up ‘What
do you think? Did you receive the study intervention or
the control intervention?’ Allocation was concealed
during data entry and analysis.
Statistical methods
Statistical analyses of primary and secondary outcomes
were carried out based on the intention-to-treat prin-
ciple. A total of 11 patients did not participate in the
teaching sessions after randomisation (figure 1).
Primary analysis was without imputation of missing
values. For sensitivity analysis of the primary end point,
we multiplied imputed missing values by the fully condi-
tional specification method using an extensive set of
baseline covariates, for example, gender, age, social
status, body mass index, diabetes duration, HbA1c and
blood pressure.30
Baseline characteristics are described by using means
and SD or frequencies.
We used unpaired t tests to compare mean scores of
comprehension and realistic expectations. We compared
average differences between planned and achieved
values of blood pressure and HbA1c using unpaired t
tests. We used Fisher’s exact tests to assess goal achieve-
ment regarding statin choice, office systolic blood pres-
sure and HbA1c (defined as reaching 80–120% of the
goal), smoking and the prioritised goal. We used the
Mann-Whitney U test to compare medication uptake
after the teaching session with 6 months follow-up
(increase/unchanged/decrease), and the χ2 test to
compare the difference in the prioritised treatment
goals between groups.
We conducted predefined additional analyses using
Fisher’s exact test to assess if risk comprehension was
associated with the level of numeracy.14 We used the
1 min Berlin Numeracy Test for general population to assess
numeracy: ‘Imagine we are throwing a five-sided die 50
times. On average, out of these 50 throws how many
times would this five-sided die show an odd number (1,
3 or 5)?’31 We also used Fisher’s exact test to assess if
comprehension was associated with the achievement of
treatment goals. For that reason, we defined two groups
of patients regarding their level of comprehension (suffi-
cient/insufficient). At least nine correctly answered
questions were considered as sufficient risk comprehen-
sion to make informed choices.32 We used analysis of vari-
ance to assess if comprehension was associated with age
and Spearman’s r correlation coefficient to assess if the
comprehension score is associated with social status. We
used Mann-Whitney U test to assess if heart attack risk
or social status is influencing the achievement of
patients’ prioritised treatment goal. We used t test for
paired samples to assess differences in comprehension
from after teaching to 6 months follow-up in the ISDM
group.
Intervention fidelity
ISDM-P teaching sessions were video-taped and analysed
to evaluate intervention fidelity and to achieve in-depth
understanding of implementation processes.14 33 In
order to maintain and optimise the fidelity of teaching
and contents, video analysis-based feedback was pro-
vided to diabetes educators after the initial sessions.
Likewise, issues with the patient teaching of the control
group were discussed and resolved after the first ses-
sions. We also assessed the number of patients who had




A total of 154 patients were randomised to either
the ISDM group (n=77) or the control group (n=77;
figure 1). Baseline characteristics were equally
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distributed (table 1). Five of 77 patients in the ISDM-P
and 6/77 in the control group did not participate in the
teaching sessions (figure 1). They did not meet
the inclusion criteria (n=5) or declined participation in
the teaching session (n=6).
Primary outcome
A total of 72 patients in the ISDM-P and 71 patients in
control group completed the questionnaire (score 0–12)
after the teaching session. The mean score for risk com-
prehension was 8.25 for the ISDM group and 2.62 for
control group (mean difference 5.63 (4.82 to 6.44);
p<0.001). The mean score of the subdomain realistic
expectations (score 0–6) was 4.51 vs 0.85 (mean difference
3.67 (3.23 to 4.11); p<0.001; table 2).
After imputation of missing values, the mean compre-
hension score was 8.27 vs 2.81 (difference 5.46 (4.64 to
6.27); p<0.001), and 4.49 vs 0.96 (difference 3.53 (3.09
to 3.97; p<0.001) for realistic expectations, respectively.
Secondary outcomes
At 6 months follow-up, there were small but statistically
significant differences between study groups regarding
risk comprehension and realistic expectations: 3.68 vs
Figure 1 Study flow (ISDM, informed shared decision-making).
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2.70 (difference 0.98 (0.15 to 1.80); p=0.021), and 1.41
vs 0.90 (difference 0.51 (0.09 to 0.93); p=0.018), respect-
ively (see online supplementary table S1). Again,
missing values did not affect results (data not shown).
The treatment goals set by the patients regarding sys-
tolic blood pressure, HbA1c levels and smoking cessa-
tion did not differ between groups. However, more
patients of ISDM-P wished to take statins (difference
28.7% (12.9% to 44.5%); p=0.001; table 3). In order to
further explore this finding, we conducted a post hoc
analysis. We compared statin prescriptions at baseline
with the treatment goal set by the patient after the
teaching session (see online supplementary table S2).
Among patients who were initially not on statins, more
of the ISDM group tended to start taking a statin (5/31
vs 2/38), whereas among patients who were already on
statins, fewer of the ISDM group wished to stop statin
treatment (3/40 vs 12/31; p=0.001).
Prioritisation of treatment goals differed significantly
between groups (see online supplementary table S3).
More patients in the ISDM group than in the control
group prioritised blood pressure control (51.4% vs
25.7%), whereas fewer patients in the ISDM group
prioritised glucose control (33.3% vs 60.0%; p=0.002).
At follow-up, more patients in the ISDM group
achieved their HbA1c goals (95.8% vs 85.7%, differ-
ence 10.1% (0.6% to 19.5%); p=0.046; table 4). As
mean HbA1c levels did not differ between groups at
baseline and follow-up, we did an additional post hoc
analysis to further explore this observation. Patients in
the ISDM group tended to set slightly higher HbA1c
goals than patients in the control group (table 3,
online supplementary table S4). The resulting mean
difference between baseline HbA1c levels and patients’
HbA1c goals was 0.1% for the ISDM group and 0.39%
for the control group. The HbA1c level of ISDM
patients at follow-up was 0.12% higher than their tar-
geted HbA1c goal, whereas patients of the control
group had 0.41% higher HbA1c levels (difference
0.29% (0.06% to 0.53%); p=0.016; see online supple-
mentary table S5).
There was no difference with respect to other treat-
ment goals. In both groups, most patients achieved their
prioritised goals (84.1% vs 87.5%; table 4).
Medication uptake did not significantly change
from baseline to directly after the teaching and to
6 months follow-up (see online supplementary tables
S6 and S7).
Additional analyses
A total of 41/143 patients correctly answered the
numeracy test with no significant difference between
groups. These patients achieved a higher questionnaire
score than patients who gave a wrong answer or did
not answer at all. After the teaching session, sufficient
risk comprehension (score ≥9) was achieved by 35 of
72 patients in the ISDM group and by no one in the






Women 36 (46.8) 36 (46.8)
Age, years 61.8 (6.5) 61.7 (6.5)
Duration of diabetes, years 13.7 (7.3) 12.7 (6.6)
Systolic blood pressure,
mm Hg
145 (20.0) 145 (16.5)
Diastolic blood pressure,
mm Hg
80 (10.2) 84 (9.9)
Body mass index, kg/m2 33.3 (7.1) 32.7 (7.4)
HbA1c, % 6.9 (0.7) 7.2 (0.7)
Total cholesterol*, mmol/L 5.4 (1.2) 4.9 (1.3)
HDL-cholesterol†, mmol/L 1.2 (0.3) 1.2 (0.3)
LDL-cholesterol‡, mmol/L 3.0 (1.0) 2.8 (1.1)
Smoker 8 (10.4) 11 (14.3)
Social status score§ 12.04 (3.8) 13.08 (3.4)
Medication for glucose
control
71 (92.2) 72 (93.5)
Insulin 46 (59.7) 44 (57.1)
Metformin 55 (71.4) 55 (71.4)
Sulfonylurea 10 (13.0) 11 (14.3)
DPP-4 inhibitors 5 (6.5) 7 (9.1)
Medication for blood
pressure control
66 (85.7) 67 (87.0)




36 (46.8) 27 (35.1)
Values are numbers (percentages) or means (SD).
*ISDM n=76, control group n=75.
†ISDM n=75, control group n=75.
‡ISDM n=75, control group n=74.
§ISDM n=75, control group n=72; social status includes
educational status, occupational status and income: score 3–21
(lower scores indicating lower social class).47
DPP-4, dipeptidyl peptidase-4; HbA1c, glycated haemoglobin;
HDL, high-density lipoprotein; ISDM, informed shared
decision-making; LDL, low-density lipoprotein.








Risk comprehension (score 0–12) 8.25 (2.86) 2.62 (1.96) 5.63 (4.82 to 6.44); <0.001
Realistic expectations (score 0–6) 4.51 (1.61) 0.85 (0.98) 3.67 (3.23 to 4.11); <0.001
Sufficient risk comprehension (score 9 or more) 35 (48.6) 0 (0) 48.6% (37.0% to 60.2%); <0.001
Values are means (SD) or numbers (percentage).
ISDM, informed shared decision-making.
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control group (table 2). There was no significant differ-
ence in the achievement of treatment goals between
patients with or without sufficient risk comprehension.
There was also no difference between age groups (40–
49, 50–59, 60–69 years). Social status did not correlate
with risk comprehension score (Spearman’s r=0.147,
p=0.085). Social status and heart attack risk did not
differ between patients achieving or not achieving their
prioritised treatment goals. In the ISDM group, the
comprehension score decreased over time (mean dif-
ference 4.62 (3.91 to 5.33); p<0.001).
Intervention fidelity
Overall, 36 ISDM teaching sessions were given by two
diabetes educators. Group size varied between one and
four patients. Twenty-four ISDM sessions were video-
taped. Analyses did not reveal major barriers. The dia-
betes educators sufficiently followed the curriculum and
adequately used the media (wall charts, worksheets,
question cards and a magnetic board). Mean duration
was 87 min (range 55–138 min). Using the tool for esti-
mation of the heart attack risk and for calculating the
individual benefit from statins were the most time con-
suming parts of the teaching session. The diabetes edu-
cators perceived the ISDM sessions as less interactive as
the usual teaching sessions. They modified the page on
glucose control of the wall chart to make the discussion
more interactive.
In the control group, a total of 34 teaching sessions
were conducted. Group size varied between one and five
patients. Initially, diabetes educators felt uncomfortable
with providing a sham intervention and appeared reluc-
tant regarding the teaching contents for stress coping
and the relaxation exercise. The research team dis-
cussed these issues with the diabetes educators and
deliberated strategies to deal with them.
Blinding of patients was assessed among the last 100
patients (the first 43 patients were inadvertently not
asked); 21 of 50 patients in the ISDM-P thought that
they received the intervention, and 16 of 50 patients of
the control group (Cohen’s κ coefficient k=0.10).
According to the protocol, patients who opt for a
change in therapy should meet a physician after the
teaching session. A total of 21 patients in the ISDM-P
and 22 control patients had a consultation with a phys-
ician at the diabetes outpatient clinic.
Deviation from the study protocol
When registering the study, we erroneously did not state
a previous diagnosis of stroke as an exclusion criterion,
although in the decision aid the target group explicitly
excludes persons with a history of stroke. Therefore,
three randomised patients (2 intervention, 1 control
group) with a history of stroke were excluded before
the teaching session, but were included in the
intention-to-treat sensitivity analysis with imputation of
missing values (figure 1). In addition, lower age limit
was changed from 45 years at study registration to
40 years with the intention to accelerate patient enrol-
ment.14 However, most patients were older than
50 years.
In the study protocol, we accidentally defined suffi-
cient comprehension as 8 of 12 correctly answered ques-
tions.14 However, we originally intended and actually set
a 75% cut-off which corresponds to ≥9 correctly
answered questions. Owing to a mistake of the








Taking statins 42/71 (59.2) 21/69 (30.4) 28.7 (12.9 to 44.5); 0.001
Stop smoking 4/8 (50.0) 4/11 (36.4) 13.6 (−31.2 to 58.5); 0.552
Average group systolic blood pressure, mm Hg 131 (7.30) 132 (8.11) −0.9 (−3.5 to 1.7); 0.419
Average group HbA1c, % 6.83 (0.49) 6.76 (0.56) 0.07 (−0.11 to 0.25); 0.492
Values are numbers (percentages) or means (SD).
HbA1c, glycated haemoglobin; ISDM, informed shared decision-making.








Statin 64/70 (91.4) 57/68 (83.8) 7.6% (−3.4% to 18.6%); 0.203
Blood pressure* 48/71 (67.6) 49/70 (70.0) −2.4% (−17.7% to 12.9%); 0.856
HbA1c* 68/71 (95.8) 60/70 (85.7) 10.1% (0.6% to 19.5%); 0.046
Smoking 4/8 (50.0) 7/12 (58.3) −8.3% (−52.9% to 36.2%); 1.000
Prioritised goal 58/69 (84.1) 56/64 (87.5) −3.4% (−15.3% to 8.5%); 0.627
Values are numbers (percentages)
*Achievement is defined as reaching a value between 80% and 120% of the defined goal.
HbA1c, glycated haemoglobin; ISDM, informed shared decision-making.
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organising study centre at Hamburg University, only the
last 100 patients were asked to rate their group
allocation.
DISCUSSION
Statement of principal findings
About half of the patients who attended the ISDM-P, but
no patient in the control group, demonstrated sufficient
comprehension of risk information. The latter is the
necessary prerequisite for informed decision-making.32
Priorities and actual preventive decisions of ISDM
patients were more in line with scientific evidence than
those of control group patients. As a result, most ISDM
patients laid emphasis on blood pressure control rather
than intensive blood glucose control. HbA1c levels and
blood pressure values were already adjusted at low levels
with no differences between groups. However, more
patients in the ISDM group achieved their HbA1c goals,
since they had set slightly higher HbA1c goals after the
teaching. While in the ISDM group more patients
wished to continue or to start statin treatment, in the
control group more patients wished to stop it.
Self-reported statin intake did not differ. It remains
unclear if the patients really adhered to their statin
medication. Nonetheless, the study results indicate that
the ISDM-P not only effects comprehension and goal
setting, but may also influence behaviour, such as treat-
ment adherence. The ISDM-P was successfully executed
by diabetes educators.
Strengths and weaknesses of the study
This study has several strengths. The study intervention
has been meticulously developed following the frame-
work for the development and evaluation of complex
interventions proposed by the UK MRC.16 This rando-
mised controlled trial was rigorously designed and con-
ducted under high fidelity conditions. Patients were
blinded against the allocation by using a sham interven-
tion in the control arm. Alongside to the trial, qualitative
methods were utilised to monitor intervention fidelity
and to evaluate possible barriers to the implementation.
Teaching programmes for people with type 2 diabetes
used to focus on blood glucose control and usually do
not provide numerical and comparative risk informa-
tion.15 34–36 Our programme is innovative. It includes
risk information and is explicitly designed to initiate
SDM as recommended in recent guidelines for the treat-
ment of type 2 diabetes.8 37
Practicability of the ISDM-P has been proven. It may
help to overcome time constraint of physicians.
There were also weaknesses. It was impossible to keep
the diabetes educators and other members of the
healthcare teams blinded. There is no information on
the primary end point at baseline. An administration of
the questionnaire at baseline, however, would probably
have produced learning effects and thus induced bias.
The study was designed as proof-of-concept, which
might limit generalisability. There were minor deviations
from study protocol.
Strengths and weaknesses in relation to other studies,
discussing important differences in results
Our findings are in accordance with results of a recent
systematic review showing that decision aids can
enhance patient involvement in various health and
treatment decisions.38 However, sharing decisions
between patients and physicians remains uninformed
unless evidence-based information is provided and
understanding of information is assured.32 39 40 Most
decision aids are used as isolated tools to prepare
patients for their consultations with the physician or
for personal reading after the medical encounter.41
Even if a decision aid includes evidence-based risk
information, patients may not be able to comprehend
the information without educational support. Without
sufficient understanding, decision making is not
informed.32
Only very few randomised controlled trials on decision
aids and SDM in the context of type 2 diabetes are avail-
able. Montori’s research group has evaluated a ‘statin
choice decision aid’ that focuses on cardiovascular pre-
vention in type 2 diabetes,42 and a ‘diabetes medication
choice decision aid’. The latter decision aid provides
patient information on antihyperglycaemic drugs,
including effects on HbA1c, weight change, risk of hypo-
glycaemia, the need for blood sugar testing, daily
routine and side effects.43 Numerical risk information
on cardiovascular outcomes is not provided. Both deci-
sion aids are designed to be used by physicians or nurses
during consultation with the patient. Both can improve
knowledge and reduce decisional conflict.42 43
Indicators of behaviour change, such as self-reported
medication adherence, were ambiguous. The ‘statin
choice decision aid’ was less successful in primary care
than at a specialised centre, when used by endocrinolo-
gists.44 In a project called ‘the Patients ANd Decision
Aids (PANDAs)’, people with type 2 diabetes received a
decision aid on starting insulin or were treated as
usual.45 The healthcare team provided the decision aid
in the waiting room directly before consultation.
Knowledge and realistic expectations improved in the
intervention group. Behaviour change was not assessed.
Denig et al13 evaluated different formats of a decision
aid for people with diabetes within a randomised con-
trolled trial. The primary outcome, patient empower-
ment in goal setting and achievement did not differ
between intervention and control group. Consultations
were not objectively evaluated, but the analysis of self-
reported questionnaires indicated that the decision aids
might not have been appropriately used.
Our ISDM-P was implemented under high fidelity con-
ditions. The provided information was relevant and evi-
dence based; the educators were trained in basic
competencies of evidence-based medicine and risk com-
munication. We implemented measures to assure that
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patients understood the information before initiating
the decision-making process.
Up to now there has been no decision aid comprehen-
sively addressing prevention of myocardial infarction in
type 2 diabetes by providing patient tailored numerical
risk information on clinical outcomes. Discussing all
options during patient consultation is impractical and
time consuming. We, therefore, developed a group
teaching programme to be provided before the consult-
ation by diabetes educators or specialised nurses. Since
structured patient education is an essential part of dia-
betes care, the ISDM-P can be easily implemented.
Implications for clinicians and policymakers
Without sufficient education, risk literacy is still low
among patients, diabetes educators and even physicians.
Patients and healthcare providers need access to under-
standable high-quality evidence-based information and
education. The ISDM-P can implement these require-
ments. Its components can also be used to adapt already
implemented educational programmes.
Unanswered questions and future research
In a number of studies, the success of SDM interventions
is measured by using the construct of ‘informed choice’
as a multidimensional outcome measure.32 Risk knowl-
edge is core part of this construct as it is required to
make informed decisions. In our study, no patient in the
control group demonstrated sufficient risk knowledge
and understanding. Thus, there was no informed
decision-making in the control group.
Physicians in our study were informed about aims,
contents and structure of the ISDM-P, but did not
receive special training in SDM. Thus, the ISDM-P may
not realign power imbalance between patients and their
physicians.46 Core concept of the ISDM-P was that dia-
betes educators would act as patient coaches. They were
supposed to organise a consultation with the physician
in case patients want to adjust treatment goals that
require changes of drug therapy. However, self-reported
statin intake remained unchanged although a relevant
proportion of patients in the control group expressed a
wish to not continue statin treatment. We have not ana-
lysed patient–physician encounters in the present study.
We could not validate self-reported adherence to statin
treatment.
Based on these findings, we developed two additional
components for the ISDM-P: (1) a single page docu-
mentation sheet for treatment goals, and (2) a struc-
tured SDM training module for physicians. Both are
aimed at optimising the consultation in terms of SDM.
First, patients document their treatment goals and there-
after, patients and physicians deliberate on these goals.
In case the physician deviates from the patient’s defined
goals, the reasons are documented on the sheet. The
patient keeps the original sheet and a copy is stored in
the patient’s record. We are evaluating the extended
ISDM-P within a cluster randomised, controlled trial in
the setting of family practices. We are assessing if
patients are more adherent to medication when this is
prescribed based on informed SDM.29
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